Year: 2020

  • Notification of Preliminary Results. Date: 4 May 2016

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that it will announce its Preliminary results for the year ended 31 December 2015 on Wednesday 4 May 2016. For further information on meetings scheduled around the Preliminary results roadshow or media enquiries, please contact Lisa Baderoon on lisa.baderoon@immupharm.com

  • First European site opened in France and Patient Recruitment Commences in Lupuzor’s™ Pivotal Phase III Study

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its pivotal Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that…

  • Confirmation of EIS and VCT Qualifying Status and Issue of Equity. £8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription

    ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received advance assurance from HM Revenue and Customs that it is a qualifying holding for the purposes of the Venture Capital Trust rules (“VCT Advance Assurance”) and a qualifying company for the purposes of the Enterprise Investment…

  • Result of GM

    ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5 February 2016, all resolutions were duly passed. Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma, said: “We are…

  • First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that the…

  • First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that the…

  • Placing and Subscription Raises £8.3 million

    ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company“), the specialist drug discovery and development company, is pleased to announce the successful completion of the conditional fund raise, comprising the Placing and Subscription, announced earlier today. The Company has conditionally raised, in aggregate, £8.3 million (before expenses) by way of the placing of 14,901,800 new ordinary shares…

  • Proposed Placing and Subscription and Notice of General Meeting: 22 February 2016

    Proposed fundraising to finance the pivotal Phase III trial for the Company’s lead product, Lupuzor™ Friday, February 5, 2016 – 10:46 ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce a proposed conditional fund raise of not less than £7.5 million. This includes a proposed conditional…

  • Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a summary of the Investigators Meeting which was held in Paris on 11th/12th  December. The key objective of the event was to bring together key specialists in the field of Lupus who will be actively involved as…

  • Lupuzor™ Pivotal Phase III Trial Recruiting First US Lupus Patients

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. The Company is pleased to confirm that…